Genital Neoplasms, Female  >>  Lynparza (olaparib)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lynparza (olaparib) / Merck (MSD), AstraZeneca
OSCA, NCT02262273: - Olaparib Standard of CAre Study

Completed
N/A
2123
Canada, Europe, RoW
Data Collection
AstraZeneca, RTI Health Solutions, A+A Healthcare Marketing Research, Freelance CRA (FCRA)
Platinum-sensitive Recurrent Serous Ovarian Cancer
04/16
04/16
NCT03079687: Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Approved for marketing
N/A
US
Olaparib tablets
AstraZeneca, Parexel
Ovarian Cancer
 
 
NCT03063710: Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

No Longer Available
N/A
Japan
olaparib
AstraZeneca
PSR Ovarian Cancer With a BRCA Mutation
 
 

Download Options